<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05031468</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00002767</org_study_id>
    <secondary_id>3UM1AI148576-02S5</secondary_id>
    <nct_id>NCT05031468</nct_id>
  </id_info>
  <brief_title>Multisite Observational Maternal and Infant Study for COVID-19</brief_title>
  <acronym>MOMI-Vax</acronym>
  <official_title>Observational, Prospective Cohort Study of the Immunogenicity and Safety of SARS-CoV-2 Vaccines Administered During Pregnancy or Postpartum and Evaluation of Antibody Transfer and Durability in Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational, non-interventional, prospective cohort study designed to collect&#xD;
      clinical information and specimens to evaluate the immune responses from pregnant individuals&#xD;
      and postpartum individuals and their infants following maternal receipt of licensed or&#xD;
      Emergency Use Authorization (EUA) severe acute respiratory syndrome coronavirus 2&#xD;
      (SARS-CoV-2) vaccines.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SARS-CoV-2, the novel coronavirus that causes Coronavirus Disease 2019 (COVID-19) disease,&#xD;
      first emerged in Wuhan, China in December 2019 and has continued to spread globally.&#xD;
      SARS-CoV-2 is highly transmissible between humans. A number of public health measures,&#xD;
      including social distancing, avoidance of large congregations, particularly indoors, and the&#xD;
      wearing of face masks, have been introduced to prevent spread of the virus. However, once&#xD;
      these measures are relaxed, unless population immunity exceeds herd immunity thresholds,&#xD;
      recrudescence of SARS-CoV-2 is expected. This underscores the urgent need for a safe and&#xD;
      effective SARS-CoV-2 vaccine.&#xD;
&#xD;
      While all vaccines in late-stage development are based on the SARS-CoV- 2 S glycoprotein,&#xD;
      they differ in other important characteristics, including manufacturing platform, number of&#xD;
      doses, and immunogenicity and safety profiles. Two messenger RNA (mRNA)-based vaccines&#xD;
      BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (NIAID-Moderna) were granted Emergency Use&#xD;
      Authorization (EUA) by the U.S. FDA based on high demonstrated efficacy against symptomatic&#xD;
      infection and severe disease in diverse populations. Janssen (Johnson &amp; Johnson) was also&#xD;
      granted EUA for their single dose nonreplicating adenovirus vector vaccine. None of these&#xD;
      large vaccine trials enrolled pregnant or lactating women (except for a small number of&#xD;
      lactating women who were enrolled in the Janssen study).&#xD;
&#xD;
      The mRNA vaccines are being distributed to prioritized population groups, and other vaccines&#xD;
      are expected to follow as they receive EUA approval. The Centers for Disease Control and&#xD;
      Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) gave a permissive&#xD;
      recommendation for pregnant individuals who are in a priority group to receive SARS-CoV-2&#xD;
      vaccines based on risk of exposure or comorbidities. In addition, some states have included&#xD;
      pregnant individuals in priority groups based on pregnancy itself being considered a&#xD;
      high-risk condition by CDC. Thus, pregnant individuals are choosing to receive these vaccines&#xD;
      under EUA, without trial data on safety and efficacy. There are neither data on the safety of&#xD;
      SARS-CoV-2 vaccines in lactating women nor on the effects of mRNA or other vaccines on the&#xD;
      breastfed infant or on milk production/excretion. Current EUA vaccines are not thought to be&#xD;
      a risk to the breastfeeding infant.&#xD;
&#xD;
      Currently, additional doses of SARS-CoV-2 vaccines are being considered to enhance durability&#xD;
      and breadth of protection, particularly against variant strains. On August 25, 2021, Pfizer&#xD;
      submitted a supplement to their Biologics License Application (BLA) for their mRNA vaccine&#xD;
      seeking approval for administration of an additional dose, and other manufacturers are&#xD;
      expected to follow. In the setting of this rapidly evolving regulatory and policy&#xD;
      environment, it is important that data on kinetics and durability of maternal and infant&#xD;
      antibodies be generated for all vaccine regimens, including any additional doses beyond the&#xD;
      primary series that may be administered to pregnant women.&#xD;
&#xD;
      Vaccines for pregnant individuals, such as influenza, tetanus and pertussis vaccines, are one&#xD;
      of the most important public health measures globally to reduce disease in both mothers and&#xD;
      infants in the first months of life. Various organizations support the position that pregnant&#xD;
      and lactating women are a priority population and must not be excluded from the SARS-CoV-2&#xD;
      vaccine allocation strategy.&#xD;
&#xD;
      The purpose of this study is to evaluate the immunogenicity and safety of various licensed or&#xD;
      EUA SARS-CoV-2 vaccines administered to pregnant or lactating women and describe the&#xD;
      transplacental antibody transfer and kinetics of antibodies in infants. The researchers will&#xD;
      also evaluate the durability of the antibodies in mothers and infants and assess breast milk&#xD;
      antibodies in lactating women. The researchers will evaluate breast milk antibodies to assess&#xD;
      potential for protection against COVID-19 in breastfed infants, similar to influenza vaccine&#xD;
      protection from influenza illness in infants of mothers vaccinated during pregnancy or&#xD;
      postpartum. The researchers anticipate including up to 4 vaccines, whether given as part of&#xD;
      the primary series or additional doses, as part of this non-interventional study. It is&#xD;
      expected that the results of this study will inform policy recommendations and personal&#xD;
      decision-making on the use of approved SARS-CoV-2 vaccines in pregnant and lactating&#xD;
      individuals.&#xD;
&#xD;
      This is an observational, non-interventional, prospective cohort study designed to collect&#xD;
      clinical information and specimens to evaluate the immune responses from approximately 2,000&#xD;
      study participants following maternal receipt of licensed or EUA SARS-CoV-2 vaccines.&#xD;
      Participants receiving a SARS-CoV-2 vaccine either during pregnancy or within 2 months of&#xD;
      delivery, and their infants, will be followed for 12 months after delivery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 6, 2021</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Geometric Mean Titer (GMT) of Serum Immunoglobulin G (IgG) Among Individuals Vaccinated During Pregnancy</measure>
    <time_frame>Baseline, 28 days post-vaccination, at delivery, postpartum months 2, 6, and 12</time_frame>
    <description>The kinetics and durability of maternal serum antibodies following receipt of SARS-CoV-2 vaccine during pregnancy will be assessed as the GMT of IgG enzyme-linked immunosorbent assay (ELISA), by vaccine type and/or platform (mRNA, viral vector, etc.).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in GMT of Neutralizing (Neut) Antibodies in Serum Among Individuals Vaccinated During Pregnancy</measure>
    <time_frame>Baseline, 28 days post-vaccination, at delivery, postpartum months 2, 6, and 12</time_frame>
    <description>The kinetics and durability of maternal serum antibodies following receipt of SARS-CoV-2 vaccine during pregnancy will be assessed as the GMT of Neut antibodies by vaccine type, platform and dose regimen.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GMT of Cord Blood IgG</measure>
    <time_frame>At delivery</time_frame>
    <description>Transplacental antibody transfer of SARS-CoV-2 antibodies among individuals vaccinated during pregnancy will be assessed as the GMT of IgG in cord blood, overall and by vaccine type, platform and dose regimen.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ratio of Cord Blood IgG to Maternal Serum IgG</measure>
    <time_frame>At delivery</time_frame>
    <description>Transplacental antibody transfer of SARS-CoV-2 antibodies among individuals vaccinated during pregnancy will be assessed as the ratio of cord blood IgG to maternal serum IgG, overall and by vaccine type, platform and dose regimen.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neut antibodies of cord blood</measure>
    <time_frame>At delivery</time_frame>
    <description>Transplacental antibody transfer of SARS-CoV-2 antibodies among individuals vaccinated during pregnancy will be assessed as the GMT of Neut antibodies in cord blood, overall and by vaccine type, platform and dose regimen.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ratio of cord blood Neut antibodies to maternal serum Neut antibodies</measure>
    <time_frame>At delivery</time_frame>
    <description>Transplacental antibody transfer of SARS-CoV-2 antibodies among individuals vaccinated during pregnancy will be assessed as the ratio of cord blood Neut antibodies to maternal Neut antibodies, overall and by vaccine type and platform.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change GMT of serum IgG in Infants Born to Individuals Vaccinated During Pregnancy</measure>
    <time_frame>At delivery, 2 months of age, 6 months of age</time_frame>
    <description>The kinetics and durability of serum SARS-CoV-2 antibodies in infants of mothers vaccinated during pregnancy will be assessed as the GMT of IgG in infants, by vaccine type, platform and dose regimen.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change GMT of Neut antibodies in Infants Born to Individuals Vaccinated During Pregnancy</measure>
    <time_frame>At delivery, 2 months of age, 6 months of age</time_frame>
    <description>The kinetics and durability of serum SARS-CoV-2 antibodies in infants of mothers vaccinated during pregnancy will be assessed as the GMT of Neut antibodies in infants, by vaccine type, platform and dose regimen.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of Maternal Outcomes</measure>
    <time_frame>At delivery</time_frame>
    <description>The frequency of maternal outcomes among individuals receiving the SARS-CoV-2 vaccine during pregnancy or postpartum will be compared to background rates in the United States, overall and by vaccine type and platform.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Infant Outcomes</measure>
    <time_frame>At delivery</time_frame>
    <description>The frequency of infant outcomes among infants born to individuals receiving the SARS-CoV-2 vaccine during pregnancy or postpartum will be compared to background rates in the United States, overall and by vaccine type and platform.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT of Serum IgG Compared to Non-Pregnant Women</measure>
    <time_frame>28 days post-vaccination</time_frame>
    <description>GMT of Serum IgG in individuals receiving different SARS-CoV-2 vaccines during pregnancy or postpartum will be compared to non-pregnant populations of women of childbearing age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT of Neut Antibodies Compared to Non-Pregnant Women</measure>
    <time_frame>28 days post-vaccination</time_frame>
    <description>GMT of Neut antibodies in individuals receiving different SARS-CoV-2 vaccines during pregnancy or postpartum will be compared to non-pregnant populations of women of childbearing age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT of Serum IgG by Gestational Age at Vaccination</measure>
    <time_frame>28 days post-vaccination</time_frame>
    <description>GMT of serum IgG in individuals receiving different SARS-CoV-2 vaccines during pregnancy will be examined by gestational age at vaccination (trimester of gestation) and interval between vaccination and delivery, by vaccine type and platform.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT of Neut Antibodies by Gestational Age at Vaccination</measure>
    <time_frame>28 days post-vaccination</time_frame>
    <description>GMT of Neut antibodies in individuals receiving different SARS-CoV-2 vaccines during pregnancy will be examined by gestational age at vaccination (trimester of gestation) and interval between vaccination and delivery, by vaccine type and platform.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT of Serum IgG by Baseline Characteristics</measure>
    <time_frame>28 days post-vaccination</time_frame>
    <description>GMT of serum IgG in individuals receiving different SARS-CoV-2 vaccines during pregnancy or postpartum will be examined by maternal age, health status, and risk status (e.g., occupation, priority vaccination group) overall and by vaccine type and platform.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT of Neut Antibodies by Baseline Characteristics</measure>
    <time_frame>28 days post-vaccination</time_frame>
    <description>GMT of Neut antibodies in individuals receiving different SARS-CoV-2 vaccines during pregnancy or postpartum will be examined by maternal age, health status, and risk status (e.g., occupation, priority vaccination group) overall and by vaccine type and platform.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT of Cord Blood IgG by Gestational Age at Vaccination</measure>
    <time_frame>At delivery</time_frame>
    <description>Transplacental antibody transfer of SARS-CoV-2 antibodies among individuals vaccinated during pregnancy will be assessed as the GMT of IgG in cord blood, by gestational age at vaccination (trimester of vaccination) and interval between vaccination and delivery, overall and by vaccine type and/or platform.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of Cord Blood IgG to Maternal Serum IgG by Gestational Age at Vaccination</measure>
    <time_frame>At delivery</time_frame>
    <description>Transplacental antibody transfer of SARS-CoV-2 antibodies among individuals vaccinated during pregnancy will be assessed as the ratio of cord blood IgG to maternal serum IgG, by gestational age at vaccination (trimester of vaccination) and interval between vaccination and delivery, overall and by vaccine type and/or platform.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT of Cord Blood Neut Antibodies by Gestational Age at Vaccination</measure>
    <time_frame>At delivery</time_frame>
    <description>Transplacental antibody transfer of SARS-CoV-2 antibodies among individuals vaccinated during pregnancy will be assessed as the GMT Neut antibodies in cord blood, by gestational age at vaccination (trimester of vaccination) and interval between vaccination and delivery, overall and by vaccine type and/or platform.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of Cord Blood Neut Antibodies to Maternal Serum Neut Antibodies by Gestational Age at Vaccination</measure>
    <time_frame>At delivery</time_frame>
    <description>Transplacental antibody transfer of SARS-CoV-2 antibodies among individuals vaccinated during pregnancy will be assessed as the ratio of cord blood Neut antibodies to maternal Neut antibodies, by gestational age at vaccination (trimester of vaccination) and interval between vaccination and delivery, overall and by vaccine type and/or platform.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT of Cord Blood IgG by Baseline Characteristics</measure>
    <time_frame>At delivery</time_frame>
    <description>Transplacental antibody transfer of SARS-CoV-2 antibodies among individuals vaccinated during pregnancy will be assessed as the GMT of IgG in cord blood, by maternal age, health status, and risk status (e.g., occupation, priority vaccination group) overall and by vaccine type and platform.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of Cord Blood IgG to Maternal Serum IgG by Baseline Characteristics</measure>
    <time_frame>At delivery</time_frame>
    <description>Transplacental antibody transfer of SARS-CoV-2 antibodies among individuals vaccinated during pregnancy will be assessed as the ratio of cord blood IgG to maternal serum IgG, by maternal age, health status, and risk status (e.g., occupation, priority vaccination group) overall and by vaccine type and platform.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT of Cord Blood Neut Antibodies by Baseline Characteristics</measure>
    <time_frame>At delivery</time_frame>
    <description>Transplacental antibody transfer of SARS-CoV-2 antibodies among individuals vaccinated during pregnancy will be assessed as the GMT Neut antibodies in cord blood, by maternal age, health status, and risk status (e.g., occupation, priority vaccination group) overall and by vaccine type and platform.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of Cord Blood Neut Antibodies to Maternal Serum Neut Antibodies by Baseline Characteristics</measure>
    <time_frame>At delivery</time_frame>
    <description>Transplacental antibody transfer of SARS-CoV-2 antibodies among individuals vaccinated during pregnancy will be assessed as the ratio of cord blood Neut antibodies to maternal Neut antibodies, by maternal age, health status, and risk status (e.g., occupation, priority vaccination group) overall and by vaccine type and platform.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in GMT of IgG in Breast Milk</measure>
    <time_frame>2 weeks postpartum, and 2, 6, and 12 months postpartum</time_frame>
    <description>The kinetics of SARS-CoV-2 antibodies in breast milk of mothers who received vaccine during pregnancy or postpartum, will be assessed as the GMT of IgG in breast milk, overall and by vaccine type and platform.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in GMT of Immunoglobulin A (IgA) in Breast Milk</measure>
    <time_frame>2 weeks postpartum, and 2, 6, and 12 months postpartum</time_frame>
    <description>The kinetics of SARS-CoV-2 antibodies in breast milk of mothers who received vaccine during pregnancy or postpartum, will be assessed as the GMT of IgA in breast milk, overall and by vaccine type and platform.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in GMT of Neut Antibodies in Breast Milk</measure>
    <time_frame>2 weeks postpartum, and 2, 6, and 12 months postpartum</time_frame>
    <description>The kinetics of SARS-CoV-2 antibodies in breast milk of mothers who received vaccine during pregnancy or postpartum, will be assessed as the GMT of Neut Antibodies in breast milk, overall and by vaccine type and platform.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in GMT of Serum IgG Among Individuals Vaccinated Postpartum</measure>
    <time_frame>Baseline, 28 days post-vaccination, postpartum months 2, 6, and 12</time_frame>
    <description>The kinetics and durability of maternal serum antibodies following receipt of SARS-CoV-2 vaccine postpartum will be assessed as the GMT of IgG, by vaccine type and/or platform.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in GMT of Neutralizing (Neut) Antibodies in Serum Among Individuals Vaccinated Postpartum</measure>
    <time_frame>Baseline, 28 days post-vaccination, postpartum months 2, 6, and 12</time_frame>
    <description>The kinetics and durability of maternal serum antibodies following receipt of SARS-CoV-2 vaccine postpartum will be assessed as the GMT of Neut antibodies, by vaccine type and/or platform.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change GMT of serum IgG in Infants Born to Individuals Vaccinated Postpartum</measure>
    <time_frame>2 months of age, 6 months of age</time_frame>
    <description>The kinetics and durability of serum SARS-CoV-2 antibodies in infants of mothers vaccinated postpartum will be assessed as the GMT of IgG in infants, by vaccine type and platform.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change GMT of Neut antibodies in Infants Born to Individuals Vaccinated Postpartum</measure>
    <time_frame>2 months of age, 6 months of age</time_frame>
    <description>The kinetics and durability of serum SARS-CoV-2 antibodies in infants of mothers vaccinated postpartum will be assessed as the GMT of Neut antibodies in infants, by vaccine type and platform.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in GMT of Serum IgG Among Individuals Receiving Additional Vaccine Dose(s)</measure>
    <time_frame>Baseline, 28 days post-vaccination, postpartum months 2, 6, and 12</time_frame>
    <description>The kinetics and durability of maternal serum antibodies following receipt of additional dose(s) of SARS-CoV-2 vaccine in pregnant individuals who received vaccine prior to pregnancy, will be assessed as the GMT of IgG in serum, by vaccine type and platform.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in GMT of Neut Antibodies Among Individuals Receiving Additional Vaccine Dose(s)</measure>
    <time_frame>Baseline, 28 days post-vaccination, postpartum months 2, 6, and 12</time_frame>
    <description>The kinetics and durability of maternal serum antibodies following receipt of additional dose(s) of SARS-CoV-2 vaccine in pregnant individuals who received vaccine prior to pregnancy, will be assessed as the GMT of Neut antibodies, by vaccine type and platform.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of COVID-19 Infection Among Pregnant Individuals</measure>
    <time_frame>Up to postpartum month 12</time_frame>
    <description>The effectiveness of SARS-CoV-2 vaccines against maternal COVID-19 infection during pregnancy and postpartum will be assessed as the incidence of laboratory confirmed COVID-19 illness during study participation assessed through passive surveillance in individuals vaccinated during pregnancy or postpartum compared to rates in unvaccinated women of childbearing age, overall and by vaccine type and platform.</description>
  </other_outcome>
  <other_outcome>
    <measure>Severity of COVID-19 Infection Among Pregnant Individuals</measure>
    <time_frame>Up to postpartum month 12</time_frame>
    <description>The effectiveness of SARS-CoV-2 vaccines against maternal COVID-19 infection during pregnancy and postpartum will be assessed as the severity of COVID-19 disease during study participation assessed through passive surveillance in individuals vaccinated during pregnancy or postpartum compared to rates in unvaccinated women of childbearing age, overall and by vaccine type and platform.</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of COVID-19 Infection Among Infants</measure>
    <time_frame>Up to 12 months of age</time_frame>
    <description>The effectiveness of maternal antibodies to provide protection against SARS-CoV-2 will be assessed by examining the incidence of COVID-19 illness in infants in the first 12 months of life. Incidence of laboratory confirmed COVID-19 during study participation is assessed through passive surveillance in infants of individuals vaccinated in pregnancy or postpartum compared to background rates in infants of unvaccinated women of childbearing age, overall and by vaccine type and platform.</description>
  </other_outcome>
  <other_outcome>
    <measure>Severity of COVID-19 Infection Among Infants</measure>
    <time_frame>Up to 12 months of age</time_frame>
    <description>The effectiveness of maternal antibodies to provide protection against SARS-CoV-2 will be assessed by examining the severity of COVID-19 illness in infants in the first 12 months of life. The severity of laboratory confirmed COVID-19 during study participation is assessed through passive surveillance in infants of individuals vaccinated in pregnancy or postpartum vs. background rates in infants of unvaccinated women of childbearing age, overall and by vaccine type and platform.</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of COVID-19 Infection Among Breastfed Infants</measure>
    <time_frame>Up to 12 months of age</time_frame>
    <description>The effectiveness of breastmilk antibodies to provide protection against SARS-CoV-2 will be assessed by examining the incidence of COVID-19 illness in infants in the first 12 months of life. The incidence of laboratory confirmed COVID-19 during study participation is assessed through passive surveillance in breastfed infants compared to not breastfed infants, by vaccine type and platform.</description>
  </other_outcome>
  <other_outcome>
    <measure>Severity of COVID-19 Infection Among Breastfed Infants</measure>
    <time_frame>Up to 12 months of age</time_frame>
    <description>The effectiveness of breastmilk antibodies to provide protection against SARS-CoV-2 will be assessed by examining the severity of COVID-19 illness in infants in the first 12 months of life. The severity of laboratory confirmed COVID-19 during study participation is assessed through passive surveillance in breastfed infants compared to not breastfed infants, by vaccine type and platform.</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of COVID-19 Infection Among Breastfed Infants by Vaccination Timing</measure>
    <time_frame>Up to 12 months of age</time_frame>
    <description>The effectiveness of breastmilk antibodies to provide protection against SARS-CoV-2 will be assessed by examining the severity of COVID-19 illness in infants in the first 12 months of life. The severity of laboratory confirmed COVID-19 during study participation is assessed through passive surveillance in breastfed infants of individuals vaccinated during pregnancy compared to postpartum, overall and by vaccine type and platform.</description>
  </other_outcome>
  <other_outcome>
    <measure>Severity of COVID-19 Infection Among Breastfed Infants by Vaccination Timing</measure>
    <time_frame>Up to 12 months of age</time_frame>
    <description>The effectiveness of breastmilk antibodies to provide protection against SARS-CoV-2 will be assessed by examining the severity of COVID-19 illness in infants in the first 12 months of life. The severity of laboratory confirmed COVID-19 during study participation is assessed through passive surveillance in breastfed infants of individuals vaccinated during pregnancy compared to postpartum, overall and by vaccine type and platform.</description>
  </other_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Group 1: Individuals vaccinated during pregnancy</arm_group_label>
    <description>Individuals who receive a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccine during pregnancy (up to 200 individuals per vaccine type)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Individuals vaccinated postpartum</arm_group_label>
    <description>Individuals who receive a SARS-CoV-2 vaccine postpartum (up to 65 individuals per vaccine type)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: Infants of individuals vaccinated during pregnancy</arm_group_label>
    <description>Infants of individuals who receive a SARS-CoV-2 vaccine during pregnancy (approximately 200 infants per vaccine type)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: Infants of individuals vaccinated postpartum</arm_group_label>
    <description>Infants of individuals who receive a SARS-CoV-2 vaccine postpartum (approximately 65 infants per vaccine type)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5: Individuals receiving additional vaccines during pregnancy</arm_group_label>
    <description>Individuals who receive additional SARS-CoV-2 vaccine(s), beyond the primary series, during pregnancy (up to 150 individuals).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6: Infants of individuals receiving additional vaccines during pregnancy</arm_group_label>
    <description>Infants of individuals who received additional SARS-CoV-2 vaccine(s), beyond the primary series, during pregnancy (approximately 150 infants).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Licensed or EUA SARS-CoV-2 vaccine</intervention_name>
    <description>Several SARS-CoV-2 vaccines utilizing different platforms (e.g., mRNA, viral vector, etc.), are available under EUA (and soon to be licensed) and are being administered to individuals who are pregnant or postpartum who belong to high-risk priority groups for vaccination. Participants will receive the SARS-CoV-2 vaccine of their choice or the type that is available to them. The researchers anticipate including up to 4 vaccines as part of this non-interventional study.</description>
    <arm_group_label>Group 1: Individuals vaccinated during pregnancy</arm_group_label>
    <arm_group_label>Group 2: Individuals vaccinated postpartum</arm_group_label>
    <arm_group_label>Group 3: Infants of individuals vaccinated during pregnancy</arm_group_label>
    <arm_group_label>Group 4: Infants of individuals vaccinated postpartum</arm_group_label>
    <arm_group_label>Group 5: Individuals receiving additional vaccines during pregnancy</arm_group_label>
    <arm_group_label>Group 6: Infants of individuals receiving additional vaccines during pregnancy</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and breast milk samples will be collected from pregnant participants. Cord blood and&#xD;
      serum samples will be collected from infant participants. Residual samples will be retained,&#xD;
      for participants who consent to have these left over specimens used for secondary research&#xD;
      studies.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant individuals and postpartum individuals (within 2 months of delivery) who will be&#xD;
        or have been vaccinated with a licensed or EUA SARS-CoV-2 vaccine, and their infants will&#xD;
        be enrolled. Individuals receiving additional SARS-CoV-2 vaccine (beyond the primary&#xD;
        series) during pregnancy will also be enrolled. Upon delivery, the infants born to&#xD;
        individuals who received vaccine during pregnancy will become study participants.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for Pregnancy Group (Group 1):&#xD;
&#xD;
          -  Pregnant individuals who are scheduled to receive or have received complete&#xD;
             vaccination series of any licensed or EUA SARS-CoV-2 vaccine during pregnancy. (NOTE:&#xD;
             no limitation health status, or gestational age at enrollment)&#xD;
&#xD;
          -  Willing and able to provide consent for study participation for herself and for her&#xD;
             infant prior to initiation of any study procedures.&#xD;
&#xD;
        Inclusion Criteria for Postpartum Group (Group 3):&#xD;
&#xD;
          -  Individuals who are scheduled to receive or who have initiated vaccination series of&#xD;
             any licensed or EUA SARS-CoV-2 vaccine within the first 2 months postpartum. (NOTE: no&#xD;
             limitation on health status).&#xD;
&#xD;
          -  Willing and able to provide consent for study participation for herself and for her&#xD;
             infant prior to initiation of any study procedures (a separate consent form will be&#xD;
             used for their infants).&#xD;
&#xD;
        Inclusion Criteria for Additional Dose(s) During Pregnancy Group (Group 5):&#xD;
&#xD;
          -  Pregnant individuals who received one dose or both doses of their primary vaccine&#xD;
             series prior to pregnancy and are scheduled to receive or have received additional&#xD;
             dose(s) of any licensed or EUA SARS-CoV-2 vaccine during pregnancy OR pregnant&#xD;
             individuals who received complete vaccination series during pregnancy and are&#xD;
             scheduled to receive or have received additional dose(s) of any licensed or EUA&#xD;
             SARS-CoV-2 vaccine during pregnancy. (NOTE: no limitation on health status or&#xD;
             gestational age at enrollment). This applies to individuals who have completed their&#xD;
             primary series and receive an additional dose during pregnancy.&#xD;
&#xD;
          -  Willing and able to provide consent for study participation for herself and for her&#xD;
             infant prior to initiation of any study procedures.&#xD;
&#xD;
        Inclusion Criteria for All Participants:&#xD;
&#xD;
          -  â‰¥18 years of age at time of enrollment&#xD;
&#xD;
          -  Understands and agrees to comply with all study procedures.&#xD;
&#xD;
          -  Agrees to sign medical release for herself and her infant to allow study staff to&#xD;
             gather pertinent medical information, pregnancy outcome data, and medical information&#xD;
             as needed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Behavioral (including a history of alcohol or drug abuse within 1 year prior to study&#xD;
             enrollment) or cognitive impairment or psychiatric disease that, in the opinion of the&#xD;
             investigator, may interfere with the subject's ability to participate in the study.&#xD;
&#xD;
          -  Any condition which, in the opinion of the investigators, may pose a health risk to&#xD;
             the subject or interfere with the evaluation of the study objectives.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Flor Munoz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Flor Munoz, MD</last_name>
    <phone>713-798-4469</phone>
    <email>florm@bcm.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martina Badell, MD</last_name>
      <phone>404-686-5958</phone>
      <email>mbadell@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Novak, MD</last_name>
      <phone>312-996-6763</phone>
      <email>rmnovak@uic.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York University Langone Vaccine Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Mulligan, MD</last_name>
      <phone>877-919-2822</phone>
      <email>Mark.Mulligan@nyulangone.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Branche, MD</last_name>
      <phone>585-273-4104</phone>
      <email>Angela_branche@urmc.rochester.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emily DeFranco, DO</last_name>
      <phone>513-558-5841</phone>
      <email>defranee@ucmail.uc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Brady, MD</last_name>
      <phone>513-636-2791</phone>
      <email>Rebecca.brady@cchmc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffery Gerber, MD</last_name>
      <phone>215-870-4750</phone>
      <email>gerberj@chop.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center (UPMC) Magee - Womens Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Bunge, MD</last_name>
      <phone>412-519-2599</phone>
      <email>bungke@upmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Flor Munoz, MD</last_name>
      <phone>713-798-4469</phone>
      <email>florm@bcm.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 26, 2021</study_first_submitted>
  <study_first_submitted_qc>August 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Flor Munoz</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Immunization</keyword>
  <keyword>Pregnancy</keyword>
  <keyword>Lactation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data will be made available for sharing for secondary research, following de-identification.</ipd_description>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data will be available for sharing immediately following publication of the results of this study, with no end date, with data sharing at the discretion of the Infectious Diseases Clinical Research Consortium (IDCRC).</ipd_time_frame>
    <ipd_access_criteria>Data will be made available for sharing for secondary research with investigators/researchers upon written request, with provision of a methodologically sound proposal. The proposal will need approval from Division of Microbiology and Infectious Diseases (DMID) and any approvals required by the site or consortium. The data will be available for only the purpose outlined in the approved proposal. Proposals can be sent to Dr. Munoz at florm@bcm.edu.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

